 Body Vision Closes $20 Million in Series C Funding Body Vision Medical, a commercial-stage medical device company specializing in lung cancer diagnostics and treatment through real-time software technologies, announced that it has closed $20 million in Series C funding. The proceeds will be used to streamline commercialization and manufacturing activities for Body Vision's LungVisionTM 2.0 Platform, which features AI Tomography, fused imaging, cloud-based machine learning and multi-modality image registration. The LungVision™ 2.0 Platform received FDA clearance in May 2019. "The LungVisionTM Platform is designed to enable the pulmonologist with easy and instant access to advanced technological capabilities within their regular procedure room," says Dorian Averbuch, founder and CEO of Body Vision Medical. "Seamlessly integrated into the standard procedure flow, the LungVisionTM Platform offers continuous support throughout all phases of a Navigation Bronchoscopy procedure. This platform includes precise tomographic tool-in-lesion confirmation and guided biopsy sampling. Body Vision Medical is uniquely equipped to provide both the physician and hospital with highly desired benefits through continuous delivery of cost-effective medical procedures." Fetch Raises $10.5M Series A For National Expansion Fetch, the first off-site package solution for apartment communities, has announced a $10.5 million Series A round of funding. Signal Peak Ventures led the round, with participation from previous investors including Silverton Partners and Capital Factory. The investment brings the Company's total funding to more than $14 million. Fetch was founded in 2016 in Dallas, TX, and has recently expanded across the country to scale with current and new clients. They currently operate in Dallas, Fort Worth, Houston, Austin, San Antonio, Seattle, Denver, Atlanta, Orlando, Tampa, Chicago, and Phoenix with Charlotte, DC, and Portland slated to round out 2019. "I'm incredibly proud of the entire Fetch team for the progress we've made in the last 3 years," said Founder & CEO Michael Patton. "Since our Seed round last summer, we've grown from 6 employees to 140, and increased sales by over 1000%. We've struck a chord in solving the package problem for the industry through exceptional customer service and consistent, reliable execution. I also take great pride in the fact that we've never lost a client." Novo Seeds Co-leads €20 Million Series A Financing in STipe Therapeutics Novo Seeds, the company creation team of Novo Holdings, announced today that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe). STipe, a spinout from the Department of Biomedicine, Aarhus University, Denmark in 2018, was founded to exploit the stimulator of interferon genes (STING) pathway, a major driver of innate immunity and regulator of tumorigenesis and autoimmune disorders. It was initially funded by Novo Seeds' internal company building engine and funded through the pre-seed grant programme of the Novo Nordisk Foundation. STipe was one of the first start-ups to be incubated at the BioInnovation Institute (BII) - a Novo Nordisk Foundation initiative. The new financing cements Novo Seeds' commitment as a player in biotech company creation, but also demonstrates how it synergistically collaborates with BII to mature early stage biotech companies. Morten Graugaard Døssing, Partner at Novo Seeds commented: "Novo Seeds' strategy is to identify, build and invest in innovative companies founded on the best science globally, and build locally. STipe Therapeutics is a great example due to its novel and truly differentiated way of modulating the STING pathway addressing key limitations of first-generation direct STING agonists which could translate to a meaningful difference to patients. It has been a true pleasure to work alongside the STipe founding team over these past three years as part of the incubation phase, and we would like to congratulate them on this important milestone for the Company. We look forward to continuing this exciting journey alongside the new investors Arix, Sunstone and Wellington." Polte Raises $12.5 Million In Series A-2 Funding Round Polte Corporation, a leading innovator in accurate Cloud Location over Cellular (C-LoC) technology, announced it has raised $12.5 million in strategic funding from experienced private investors. The Series A-2 funding will enable the company to focus on deployments of commercial and industrial applications of Polte's patented alternative to GPS. "This round of funding from committed and seasoned investors enables us to expand our team to deploy and deliver our affordable, accurate and secure location services," said Ed Chao, chief executive officer, Polte. "Businesses across all sectors and geographies know that location services are essential in enabling organizations to have unprecedented visibility into their assets and operations. Polte technology is less expensive to deploy at scale, an order of magnitude more accurate, and more secure than current approaches to location information." Tenaya Therapeutics Closes $92 Million Series B Financing Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, announced the successful completion of a $92 million Series B financing. The financing round was led by Casdin Capital and included GV, The Column Group, and additional undisclosed new and existing investors. Tenaya has raised $142 million since its founding by scientists at the Gladstone Institutes and University of Texas Southwestern Medical Center in October 2016. Proceeds from the financing will be used to advance and to expand Tenaya's pipeline and to strengthen the science, capabilities, and intellectual property that provide the foundation for Tenaya's multi-modality product platforms – Cellular Regeneration, Gene Therapy, and Precision Medicine. "We are now well-resourced to build on our capabilities in research and manufacturing, and to accelerate the development of our lead gene therapy and small molecule projects for both orphan and prevalent heart diseases towards the clinic," said Faraz Ali, Chief Executive Officer of Tenaya. "We are pleased to have a group of experienced private and public investors led by Casdin Capital and The Column Group who support the potential for Tenaya's science to transform the treatment of heart failure, the leading cause of death in the world." Nabsys Raises $21 Million Equity Round Led by Hitachi High-Technologies Nabsys, the pioneer in high-definition genome mapping, announced that it has closed on a $21 million equity round led by Hitachi High-Technologies Corporation. Nabsys will use the funding to finalize product development and support global commercial launch of their HD-Mapping™ whole-genome electronic mapping platform. HD-Mapping has applications in a wide variety of key research applications, including de novo assembly, structural variant analysis, metagenome characterization, and strain identification, as well as in next-generation cytogenetics. Nabsys electronic mapping enables routine, scalable analysis of genomic structural variation. Mr. Tsuyoshi Ogino, General Manager, Innovation Division at Hitachi High-Technologies said, "There is a strong need for accurate, robust, and scalable genomic structural analysis for cytogenetic, cancer, and infectious disease research. Hitachi High-Technologies determined that the Nabsys HD-Mapping approach effectively supports this need. The company is also a strong fit with our strategy for continued advanced R&D with strategic investments in life sciences." "This investment round will help Nabsys fulfill its mission to make the analysis of large- and intermediate-scale genomic variation as routine, accurate, and cost-effective as the analysis of single-nucleotide variation," said Barrett Bready, M.D., Founder and CEO at Nabsys. Shah Capital Invests US$11 Million in ReneSola ReneSola Ltd (www.renesolapower.com) a leading fully integrated solar project developer, announced that the Company entered into a definitive share purchase agreement ("the Share Purchase Agreement") dated as of September 29, 2019 with Shah Capital Opportunity Fund LP ("Shah"), according to which the Company would issue and sell to Shah and Shah would purchase from the Company 100,000,000 newly issued ordinary shares at a price of US$0.11 per Share, for a total consideration of US$11 million (the "Transaction"). The Transaction closed today. The newly issued shares are subject to a 180 day lockup period. Net proceeds from the transaction are intended to be used to expand ReneSola's global project development activities. Ms. Shelley Xu, Chief Executive Officer of ReneSola, commented, "This capital infusion substantially strengthens our balance sheet, enabling us to accelerate our growth and more quickly execute our transformation into an asset-light solar developer. We appreciate the support of Shah Capital, which has been a strategic investor in ReneSola for some time." Lattice Raises $25m Series C to Continue Empowering Leaders to Develop High-Performing Teams Lattice, the people management platform, announced $25 million in Series C funding today in a round led by Tiger Global. This round comes on the heels of the strongest quarter in company history, more than doubled user counts since the beginning of the year, and its funding in April, which the company is using to further accelerate its category-leading growth. Lattice's platform helps people leaders build high-performing teams by equipping managers with tools to drive growth and productivity through continuous performance management. Lattice also provides People teams with insights to act on real-time engagement feedback that drive company-wide impact. Since its launch in 2016, Lattice has quickly built a customer base of over 1,400 leading companies including Slack, Glossier, Reddit, Cruise, and Coinbase. XTransfer completes $15M to accelerate provision of global financial services for foreign trade XTransfer, a leading provider of cross-border financial services for China based foreign trade enterprises, announced the completion of $15m Series B-1 financing, which was led by the eWTP Fund and included China Merchants Venture Capital, 01VC, Yunqi Partners, and Gaorong Capital. The financing will be used toward further expansion of XTransfer's global financial network, applications for licensing in various countries, team and technology upgrades, and marketing. XTransfer, founded in May 2017 is headquartered in Shanghai. Being a global company from the start XTransfer has branches and relevant licenses in Hong Kong, the UK, Canada, the United States, Japan, and Australia. By building a strong global financial network, XTransfer is able to provide global financial service solutions for Chinese SMEs, such as cross-border and local collection, payment, foreign exchange, lending, and other treasury management services. Mr. Jiang Dawei, a partner at eWTP, said that the eWTP Fund is dedicated to technological innovation and global development of innovative businesses in regions involved in the Belt and Road Initiative (BRI). As the BRI is being implemented, more and more SMEs are going abroad to deploy their business resources on a global scale. XTransfer is set on helping these SME's greatly reduce the financial costs associated with their expanding global business. We highly agree with the business and vision of the company. We believe that financial technology enterprises, such as XTransfer, will play a vital role in the construction of a new global financial network. CleverTap Completes $35 Million Series C Funding to Drive Global Growth CleverTap, the leading AI-powered customer lifecycle and user retention platform, today announced it has completed its Series C investment round, allowing further acceleration as a global leader in mobile app marketing. Growing at 250% YoY since 2015, CleverTap intends to use the funds to build out its new US-based engineering hub, add enhanced predictive capabilities to its market-leading platform, and fuel an aggressive global go-to-market expansion strategy. CleverTap's Series C round is led by existing investors Tiger Global Management and Sequoia India. This new funding increases CleverTap's outside investment to $61 million since the beginning of 2019 — a period that has seen the company's valuation more than double from $150 million to $385 million. "Leading companies know that the key to driving revenue growth in the mobile app space is increasing user retention and raising long-term customer lifetime value," said Sunil Thomas, co-founder and CEO of CleverTap. "We're in the unique position to deliver a holistic solution that not only provides actionable customer insights but also delivers the right message to drive deeper engagement based on real-time customer usage—all at scale. This latest round of funding will enable CleverTap to help more companies achieve their retention goals as they build long-lasting relationships with their customers." Media Partner - News and Articles> WORLD BIZ MAGAZINE - AUTUMN 2019 ISSUE WORLD BANK AWARDS 2019 - THE BEST BANKS FOR BUSINESS CSR LEADER 100 - THE MOST RESPONSIBLE COMPANIES WORLD FDI AWARDS 2019 - THE BEST INVESTMENT DESTINATIONS DESTIG ART INVESTMENT: TOP EMERGING ARTISTS Comments are closed.
|
|
